search
Back to results

Effect of Selective iNOS Inhibition During Human Endotoxemia

Primary Purpose

Endotoxemia

Status
Completed
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
Aminoguanidine
endotoxin
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Endotoxemia focused on measuring Endotoxemia, Aminoguanidine

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy volunteers Exclusion Criteria: tendency towards fainting alcohol abuse nicotine abuse drugs abuse

Sites / Locations

  • Radboud University Nijmegen Medical Centre

Outcomes

Primary Outcome Measures

Hemodynamics
Markers of Inflammation
Cytokines
Markers of Renal Injury
Inducible NO synthase expression
NO-metabolites
Mediators of Vascular reactivity
Sensitivity to norepinephrine
Endothelial-dependent vasorelaxation

Secondary Outcome Measures

Full Information

First Posted
September 12, 2005
Last Updated
April 14, 2008
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00184990
Brief Title
Effect of Selective iNOS Inhibition During Human Endotoxemia
Official Title
Effect of Selective iNOS Inhibition During Human Endotoxemia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
January 2005 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
September 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Radboud University Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Sepsis or endotoxemia is manifested by hypotension, resistance to vasopressors, myocardial depression,and altered organ blood flow distribution. The mechanisms underlying the cardiovascular dysfunction during sepsis are complex; however, they are partially mediated by an uncontrolled production of NO by inducible NO synthase (iNOS).Control subjects received 2 ng/kg E. coli endotoxin, whereas the active intervention group received endotoxin in the presence of selective iNOS-inhibitor aminoguanidine. Hemodynamics, vascular responses to norepinephrine, acetylcholine and sodium nitroprusside, as well as circulating cytokines and other mediators of inflammation were measured. We tested the hypothesis that inhibition of NO-synthesis prevented the LPS-mediated insensitivity to noradrenalin and endothelial-dependent vasorelaxation. Furthermore, we tested whether NO participates in occurrence of the endotoxin tolerance in humans by using the iNOS inhibitor aminoguanidine on healthy volunteers with endotoxemia. At 0; 2 and 4 hours after the LPS challenge whole blood was stimulated with five TLR agonists in vitro and pro- and anti-inflammatory cytokines were measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endotoxemia
Keywords
Endotoxemia, Aminoguanidine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Aminoguanidine
Intervention Type
Drug
Intervention Name(s)
endotoxin
Primary Outcome Measure Information:
Title
Hemodynamics
Time Frame
24 hrs after LPS administration
Title
Markers of Inflammation
Time Frame
24 hrs after LPS administration
Title
Cytokines
Time Frame
24 hrs after LPS administration
Title
Markers of Renal Injury
Time Frame
24 hrs after LPS administration
Title
Inducible NO synthase expression
Time Frame
24 hrs after LPS administration
Title
NO-metabolites
Time Frame
24 hrs after LPS administration
Title
Mediators of Vascular reactivity
Time Frame
24 hrs after LPS administration
Title
Sensitivity to norepinephrine
Time Frame
24 hrs after LPS administration
Title
Endothelial-dependent vasorelaxation
Time Frame
24 hrs after LPS administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers Exclusion Criteria: tendency towards fainting alcohol abuse nicotine abuse drugs abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Nijmegen Medical Centre
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500HB
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Effect of Selective iNOS Inhibition During Human Endotoxemia

We'll reach out to this number within 24 hrs